`
`Carl Stern‘fl | Shield Therapeutics
`
`% SHIELD
`
`INIIAPIUTIFS 5’1:
`
`People
`
`Our achievements '-.voulo' not be possible witho:..lt the outstanding team that mate up
`
`Sé'l?e|c£TI1eraoelltics' .staff_ management and board ofciir'ector's.
`
`CHIEF EXECUTIVE OFFICER sun CO-FOUNDER
`
`Carl Ste rritt
`
`With approximately 20 years' of management and executive level experience in pharmaceutical development
`
`and commercialisation in both large and small companyr settings. Carl has led the Company as its CEO since
`
`he co-founded the Group in 2008 together with Dr.Christian Schweiger.
`
`Previously. Carl held senior management roles at United Therapeutics and Encysive Pharmaceuticals. working
`
`on innovative therapies for the treatment of pulmonary arterial hypertension. Carl joined United
`
`Therapeutics to establish the company’s European operations in preparation for the marketing approval of
`
`Remodulin®. running the subsidiary for six years. In collaboration with physicians in Germany. he was
`
`responsible for and holds patents related to United Therapeutics decision to develop and commerciali
`
`treprostinil: now successfully commercialised in the US as TwasoT“. Carl was instrumental in the success. u.
`
`commercial launch of ThelinTM and the rapid growth of Encysive’s European operations. Carl founded the
`
`Group after Encysive was acquired by Pfizer Inc. for more than SSOOm.
`
`BACK TO TEAM
`
`htlpsu'fwwwshleldmerapeufica.comftearru'oarl-eterriw
`
`1:3
`
`UNITED THERAPEUTICS, ex. 2025
`WATSON LABORATORIES V. UNITED THERAPEUTICS. lPR2017-D1621
`Page 1 of 1
`
`